S&P 500   2,989.69 (-0.20%)
DOW   27,001.98 (-0.08%)
QQQ   193.04 (-0.25%)
AAPL   234.37 (-0.40%)
FB   189.55 (+0.35%)
MSFT   140.41 (-0.82%)
GOOGL   1,243.00 (+0.06%)
AMZN   1,777.43 (+0.57%)
CGC   19.73 (-1.84%)
NVDA   194.21 (-1.10%)
MU   45.16 (-2.80%)
BABA   177.12 (+1.04%)
GE   8.90 (+0.11%)
TSLA   259.75 (+0.72%)
AMD   30.81 (+0.29%)
T   37.79 (-0.29%)
F   9.07 (+0.00%)
ACB   3.61 (-3.99%)
PRI   123.87 (+0.16%)
NFLX   286.28 (+0.71%)
BAC   30.17 (+1.48%)
GILD   65.35 (+0.08%)
DIS   130.86 (+0.85%)
S&P 500   2,989.69 (-0.20%)
DOW   27,001.98 (-0.08%)
QQQ   193.04 (-0.25%)
AAPL   234.37 (-0.40%)
FB   189.55 (+0.35%)
MSFT   140.41 (-0.82%)
GOOGL   1,243.00 (+0.06%)
AMZN   1,777.43 (+0.57%)
CGC   19.73 (-1.84%)
NVDA   194.21 (-1.10%)
MU   45.16 (-2.80%)
BABA   177.12 (+1.04%)
GE   8.90 (+0.11%)
TSLA   259.75 (+0.72%)
AMD   30.81 (+0.29%)
T   37.79 (-0.29%)
F   9.07 (+0.00%)
ACB   3.61 (-3.99%)
PRI   123.87 (+0.16%)
NFLX   286.28 (+0.71%)
BAC   30.17 (+1.48%)
GILD   65.35 (+0.08%)
DIS   130.86 (+0.85%)
Log in

X4 Pharmaceuticals Stock Price, News & Analysis (NASDAQ:XFOR)

$12.24
-0.12 (-0.97 %)
(As of 10/16/2019 04:00 PM ET)
Today's Range
$11.80
Now: $12.24
$12.98
50-Day Range
$11.61
MA: $13.02
$15.59
52-Week Range
$6.90
Now: $12.24
$29.46
Volume54,733 shs
Average Volume37,690 shs
Market Capitalization$152.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XFOR
CUSIPN/A
CIKN/A
Phone857-529-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.50 million
Book Value$9.05 per share

Profitability

Net Income$-43,020,000.00

Miscellaneous

EmployeesN/A
Market Cap$152.14 million
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable

Receive XFOR News and Ratings via Email

Sign-up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.


X4 Pharmaceuticals (NASDAQ:XFOR) Frequently Asked Questions

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals Inc (NASDAQ:XFOR) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.18. View X4 Pharmaceuticals' Earnings History.

When is X4 Pharmaceuticals' next earnings date?

X4 Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for X4 Pharmaceuticals.

What price target have analysts set for XFOR?

3 brokerages have issued twelve-month price targets for X4 Pharmaceuticals' stock. Their predictions range from $27.00 to $27.00. On average, they expect X4 Pharmaceuticals' share price to reach $27.00 in the next year. This suggests a possible upside of 120.6% from the stock's current price. View Analyst Price Targets for X4 Pharmaceuticals.

What is the consensus analysts' recommendation for X4 Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for X4 Pharmaceuticals.

Has X4 Pharmaceuticals been receiving favorable news coverage?

Press coverage about XFOR stock has trended positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. X4 Pharmaceuticals earned a news impact score of 2.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for X4 Pharmaceuticals.

Are investors shorting X4 Pharmaceuticals?

X4 Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 229,800 shares, an increase of 22.6% from the August 30th total of 187,500 shares. Based on an average daily trading volume, of 37,900 shares, the days-to-cover ratio is currently 6.1 days. Approximately 2.1% of the company's shares are sold short. View X4 Pharmaceuticals' Current Options Chain.

Who are some of X4 Pharmaceuticals' key competitors?

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Aeglea Bio Therapeutics (AGLE), ADMA Biologics (ADMA), Amarin (AMRN), Aqua Metals (AQMS), eHealth (EHTH), Evolus (EOLS), Iovance Biotherapeutics (IOVA), Opko Health (OPK), Presidio (PSDO) and Sangamo Therapeutics (SGMO).

Who are X4 Pharmaceuticals' key executives?

X4 Pharmaceuticals' management team includes the folowing people:
  • Dr. Paula Ragan, Founder, CEO, Pres, Sec. & Director (Age 48)
  • Dr. Renato T. Skerlj Ph.D., Founder and Member of Scientific Advisory Board
  • Mr. Adam S. Mostafa, CFO, Treasurer & Assistant Sec. (Age 39)
  • Ms. Ronny Mosston, VP of HR
  • Dr. Robert David Arbeit M.D., Sr. VP of Clinical Devel. and Translational Research (Age 71)

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $12.24.

How big of a company is X4 Pharmaceuticals?

X4 Pharmaceuticals has a market capitalization of $152.14 million and generates $3.50 million in revenue each year. View Additional Information About X4 Pharmaceuticals.

What is X4 Pharmaceuticals' official website?

The official website for X4 Pharmaceuticals is http://www.x4pharma.com/.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-529-8300 or via email at [email protected]


MarketBeat Community Rating for X4 Pharmaceuticals (NASDAQ XFOR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  16 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  38
MarketBeat's community ratings are surveys of what our community members think about X4 Pharmaceuticals and other stocks. Vote "Outperform" if you believe XFOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XFOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel